Leslie J. Crofford
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Leslie J. Crofford has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Brent E. Appleton
University of Michigan
2 shared publicationsHuimin Bian
Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA
2 shared publicationsAnia Korszun
University of Wales College of Medicine, Cardiff, Wales
1 shared publicationBlake J. Roessler
Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA
1 shared publication- Bruce Solitar
New York University Medical Center
1 shared publication Christine B. Brucksch
Department of Psychiatry, University of Michigan School of Medicine, Ann Arbor, MI, USA
1 shared publication
Latest Publications
- 1 March 2005
- Published by Wiley in The Journal of Gene Medicine
- Vol. 7 (3) , 288-296
Adenovirus binding to cultured synoviocytes triggers signaling through MAPK pathways and induces expression of cyclooxygenase-2
Background Recombinant adenovirus can be administered in vivo to achieve transduction of a number of cell types including human synoviocytes. Immunogenicity of adenoviruses has limited their utility as vectors for gene delivery; however, specific mechanisms underlying the acute inflammatory response to adenovirus are not well understood. Activation of a number of signal transduction pathways occurs rapidly upon adenovirus binding to cell‐surface receptors. We investigated stimulated expression of mitogen‐activated protein kinases (MAPKs), cyclooxygenase‐2 (COX‐2) and prostaglandin E2 (PGE2) in human primary synovial fibroblasts to adenovirus expressing the E. coli β‐galactosidase gene. Methods Cultured rheumatoid synoviocytes were exposed to transduction‐competent Ad/RSVlacZ recombinant adenovirus or transduction‐incompetent (psoralen/UV‐irradiated) Ad/RSVlacZ. The effects on COX‐2 expression, PGE2 levels and MAPK signaling in synoviocytes were assessed using a combination of reverse‐transcription polymerase chain reaction amplification and immunoblotting. Results Adenovirus treatment of synoviocytes increased levels of COX‐2 mRNA and protein as well as PGE2. Psoralen‐treated transcriptionally inactive adenovirus was equivalent to untreated adenovirus for early COX‐2 induction suggesting that viral genes were not required. Adenovirus treatment stimulated phosphorylation of ERK‐1/‐2, p38 MAPK, and JNK. Inhibition of the ERK and p38 MAPK pathways inhibited COX‐2 expression and PGE2 production. Conclusions Taken together, these data demonstrate that a MAPK‐dependent increase in COX‐2 results in local prostaglandin production. These findings have clinical implications for use of adenovirus as vectors for in vivo gene delivery. Copyright © 2004 John Wiley & Sons, Ltd.
- 1 March 2005
- Published by Wiley in The Journal of Gene Medicine
- Vol. 7 (3) , 288-296
Adenovirus binding to cultured synoviocytes triggers signaling through MAPK pathways and induces expression of cyclooxygenase-2
Background Recombinant adenovirus can be administered in vivo to achieve transduction of a number of cell types including human synoviocytes. Immunogenicity of adenoviruses has limited their utility as vectors for gene delivery; however, specific mechanisms underlying the acute inflammatory response to adenovirus are not well understood. Activation of a number of signal transduction pathways occurs rapidly upon adenovirus binding to cell‐surface receptors. We investigated stimulated expression of mitogen‐activated protein kinases (MAPKs), cyclooxygenase‐2 (COX‐2) and prostaglandin E2 (PGE2) in human primary synovial fibroblasts to adenovirus expressing the E. coli β‐galactosidase gene. Methods Cultured rheumatoid synoviocytes were exposed to transduction‐competent Ad/RSVlacZ recombinant adenovirus or transduction‐incompetent (psoralen/UV‐irradiated) Ad/RSVlacZ. The effects on COX‐2 expression, PGE2 levels and MAPK signaling in synoviocytes were assessed using a combination of reverse‐transcription polymerase chain reaction amplification and immunoblotting. Results Adenovirus treatment of synoviocytes increased levels of COX‐2 mRNA and protein as well as PGE2. Psoralen‐treated transcriptionally inactive adenovirus was equivalent to untreated adenovirus for early COX‐2 induction suggesting that viral genes were not required. Adenovirus treatment stimulated phosphorylation of ERK‐1/‐2, p38 MAPK, and JNK. Inhibition of the ERK and p38 MAPK pathways inhibited COX‐2 expression and PGE2 production. Conclusions Taken together, these data demonstrate that a MAPK‐dependent increase in COX‐2 results in local prostaglandin production. These findings have clinical implications for use of adenovirus as vectors for in vivo gene delivery. Copyright © 2004 John Wiley & Sons, Ltd.
- 1 July 2004
- Published by Springer Nature in Current Rheumatology Reports
- Vol. 6 (4) , 274-280
Pharmaceutical treatment options for fibromyalgia
Fibromyalgia syndrome (FMS) is a chronic multisymptom illness characterized by widespread pain and associated with neuropsychological symptoms including fatigue, unrefreshing sleep, cognitive dysfunction, anxiety, and depression. A discreet cause of FMS has not been identified. It is likely that multiple mechanisms give rise to symptom expression. Understanding specific etiologic factors and pathogenic mechanisms in individual patients will allow clinicians to determine treatments that are most effective for a given patient. Available evidence implicates the central nervous system as key in maintaining pain and other core symptoms of FMS. The approach to treatment of pain will typically address these central mechanisms. Nonpain symptoms may be treated by drugs affecting similar central neurochemicals. This paper will review the rationale for the different types of pharmaceutical treatments that may be useful for the treatment of FMS and issues regarding new drug development for this indication.
- 1 July 2004
- Published by Springer Nature in Current Rheumatology Reports
- Vol. 6 (4) , 274-280
Pharmaceutical treatment options for fibromyalgia
Fibromyalgia syndrome (FMS) is a chronic multisymptom illness characterized by widespread pain and associated with neuropsychological symptoms including fatigue, unrefreshing sleep, cognitive dysfunction, anxiety, and depression. A discreet cause of FMS has not been identified. It is likely that multiple mechanisms give rise to symptom expression. Understanding specific etiologic factors and pathogenic mechanisms in individual patients will allow clinicians to determine treatments that are most effective for a given patient. Available evidence implicates the central nervous system as key in maintaining pain and other core symptoms of FMS. The approach to treatment of pain will typically address these central mechanisms. Nonpain symptoms may be treated by drugs affecting similar central neurochemicals. This paper will review the rationale for the different types of pharmaceutical treatments that may be useful for the treatment of FMS and issues regarding new drug development for this indication.
- 26 February 2004
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 18 (4) , 314-325
Basal circadian and pulsatile ACTH and cortisol secretion in patients with fibromyalgia and/or chronic fatigue syndrome
- 26 February 2004
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 18 (4) , 314-325
Basal circadian and pulsatile ACTH and cortisol secretion in patients with fibromyalgia and/or chronic fatigue syndrome
- Open Access
- 9 December 2002
- Vol. 5 (1) , 25-7
COX-2: Where are we in 2003? - Specific cyclooxygenase-2 inhibitors and aspirin-exacerbated respiratory disease.
The use of analgesic anti-inflammatory agents in patients with asthma is clinically challenging because of the prevalence (10-20%) of aspirin hypersensitivity. Aspirin-exacerbated respiratory disease (AERD), or aspirin-induced asthma, is characterized by asthma and rhinitis triggered by the ingestion of aspirin and non-steroidal anti-inflammatory drugs. AERD is associated with upper and lower respiratory-tract mucosal inflammation, progressive sinusitis, nasal polyposis, and asthma regardless of whether patients avoid triggering drugs. The mechanism underlying the propensity of aspirin and non-steroidal anti-inflammatory drugs to cause this reaction is thought to involve inhibition of the synthesis of protective prostaglandins (PGs), resulting in an increase in the synthesis of cysteinyl leukotrienes by eosinophils and mast cells. Clinical data suggest that protective PGs are derived from cyclooxygenase (COX)-1 because studies have now confirmed that drugs specifically inhibiting COX-2 are not cross-reactive with aspirin in patients with AERD.
- 9 December 2002
- Vol. 5 (1) , 25-7
Open AccessCOX-2: Where are we in 2003? - Specific cyclooxygenase-2 inhibitors and aspirin-exacerbated respiratory disease.
The use of analgesic anti-inflammatory agents in patients with asthma is clinically challenging because of the prevalence (10-20%) of aspirin hypersensitivity. Aspirin-exacerbated respiratory disease (AERD), or aspirin-induced asthma, is characterized by asthma and rhinitis triggered by the ingestion of aspirin and non-steroidal anti-inflammatory drugs. AERD is associated with upper and lower respiratory-tract mucosal inflammation, progressive sinusitis, nasal polyposis, and asthma regardless of whether patients avoid triggering drugs. The mechanism underlying the propensity of aspirin and non-steroidal anti-inflammatory drugs to cause this reaction is thought to involve inhibition of the synthesis of protective prostaglandins (PGs), resulting in an increase in the synthesis of cysteinyl leukotrienes by eosinophils and mast cells. Clinical data suggest that protective PGs are derived from cyclooxygenase (COX)-1 because studies have now confirmed that drugs specifically inhibiting COX-2 are not cross-reactive with aspirin in patients with AERD.
- Open Access
- 8 May 2002
- Published by Wiley in Arthritis & Rheumatism
- Vol. 46 (5) , 1136-1138
Fibromyalgia: Where are we a decade after the American College of Rheumatology classification criteria were developed?
- 8 May 2002
- Published by Wiley in Arthritis & Rheumatism
- Vol. 46 (5) , 1136-1138
Open AccessFibromyalgia: Where are we a decade after the American College of Rheumatology classification criteria were developed?
- 1 May 2002
- Published by Wolters Kluwer Health in Current Opinion in Rheumatology
- Vol. 14 (3) , 225-230
Specific cyclooxygenase-2 inhibitors: what have we learned since they came into widespread clinical use?
Specific inhibitors of cyclooxygenase-2 were introduced into widespread clinical use in 1999. Since that time, celecoxib and rofecoxib have become two of the most commonly prescribed medications in the United States. Clinical trials using these medications for arthritis and pain have uniformly demonstrated efficacy superior to that of placebo and similar to that of nonsteroidal anti-inflammatory drugs. However, controversy surrounding the proper place of cyclooxygenase-2 inhibitors in the hierarchy of treatment for arthritis continues, based primarily on their higher cost compared with that of acetaminophen and nonsteroidal anti-inflammatory drugs. A decreased risk of gastrointestinal toxicity remains the primary justification for using the more expensive cyclooxygenase-2 inhibitors in preference to nonsteroidal anti-inflammatory drugs. The renal and cardiovascular effects of rofecoxib and celecoxib have been investigated in relation to nonsteroidal anti-inflammatory drugs and to one another. The data with respect to alteration in renal function, lower extremity edema, and hypertension indicates that cyclooxygenase-2 inhibitors affect the kidney in a manner similar to that of nonsteroidal anti-inflammatory drugs. The data comparing the cyclooxygenase-2 inhibitors is difficult to interpret because it is not clear that comparable doses have been used in clinical trials. The potential thrombogenic risk of cyclooxygenase-2 inhibitors remains controversial, and conflicting data exist. It remains important to increase our understanding of the place of these agents in clinical practice from the perspective of efficacy, toxicity, and cost.
- 1 May 2002
- Published by Wolters Kluwer Health in Current Opinion in Rheumatology
- Vol. 14 (3) , 225-230
Specific cyclooxygenase-2 inhibitors: what have we learned since they came into widespread clinical use?
Specific inhibitors of cyclooxygenase-2 were introduced into widespread clinical use in 1999. Since that time, celecoxib and rofecoxib have become two of the most commonly prescribed medications in the United States. Clinical trials using these medications for arthritis and pain have uniformly demonstrated efficacy superior to that of placebo and similar to that of nonsteroidal anti-inflammatory drugs. However, controversy surrounding the proper place of cyclooxygenase-2 inhibitors in the hierarchy of treatment for arthritis continues, based primarily on their higher cost compared with that of acetaminophen and nonsteroidal anti-inflammatory drugs. A decreased risk of gastrointestinal toxicity remains the primary justification for using the more expensive cyclooxygenase-2 inhibitors in preference to nonsteroidal anti-inflammatory drugs. The renal and cardiovascular effects of rofecoxib and celecoxib have been investigated in relation to nonsteroidal anti-inflammatory drugs and to one another. The data with respect to alteration in renal function, lower extremity edema, and hypertension indicates that cyclooxygenase-2 inhibitors affect the kidney in a manner similar to that of nonsteroidal anti-inflammatory drugs. The data comparing the cyclooxygenase-2 inhibitors is difficult to interpret because it is not clear that comparable doses have been used in clinical trials. The potential thrombogenic risk of cyclooxygenase-2 inhibitors remains controversial, and conflicting data exist. It remains important to increase our understanding of the place of these agents in clinical practice from the perspective of efficacy, toxicity, and cost.
- 1 March 2002
- Published by Elsevier in Endocrinology and Metabolism Clinics of North America
- Vol. 31 (1) , 1-13
The hypothalamic–pituitary–adrenal axis in the pathogenesis of rheumatic diseases
- 1 March 2002
- Published by Elsevier in Endocrinology and Metabolism Clinics of North America
- Vol. 31 (1) , 1-13
The hypothalamic–pituitary–adrenal axis in the pathogenesis of rheumatic diseases
- 1 December 2001
- Published by Elsevier in Gastroenterology Clinics of North America
- Vol. 30 (4) , 863-876
PROSTAGLANDIN BIOLOGY
- 1 December 2001
- Published by Elsevier in Gastroenterology Clinics of North America
- Vol. 30 (4) , 863-876
PROSTAGLANDIN BIOLOGY
- Open Access
- 1 July 2001
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 167 (1) , 469-474
Microsomal Prostaglandin E Synthase Is Regulated by Proinflammatory Cytokines and Glucocorticoids in Primary Rheumatoid Synovial Cells
The selective induction of PGE2 synthesis in inflammation suggests that a PGE synthase may be linked to an inducible pathway for PG synthesis. We examined the expression of the recently cloned inducible microsomal PGE synthase (mPGES) in synoviocytes from patients with rheumatoid arthritis, its modulation by cytokines and dexamethasone, and its linkage to the inducible cyclooxygenase-2. Northern blot analysis showed that IL-1β or TNF-α treatment induces mPGES mRNA from very low levels at baseline to maximum levels at 24 h. IL-1β-induced mPGES mRNA was inhibited by dexamethasone in a dose-dependent fashion. Western blot analysis demonstrated that mPGES protein was induced by IL-1β, and maximum expression was sustained for up to 72 h. There was a coordinated up-regulation of cyclooxygenase-2 protein, although peak expression was earlier. Differential Western blot analysis of the microsomal and the cytosolic fractions revealed that the induced expression of mPGES protein was limited to the microsomal fraction. The detected mPGES protein was catalytically functional as indicated by a 3-fold increase of PGES activity in synoviocytes following treatment with IL-1β; this increased synthase activity was limited to the microsomal fraction. In summary, these data demonstrate an induction of mPGES in rheumatoid synoviocytes by proinflammatory cytokines. This novel pathway may be a target for therapeutic intervention for patients with arthritis.
- 1 July 2001
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 167 (1) , 469-474
Open AccessMicrosomal Prostaglandin E Synthase Is Regulated by Proinflammatory Cytokines and Glucocorticoids in Primary Rheumatoid Synovial Cells
The selective induction of PGE2 synthesis in inflammation suggests that a PGE synthase may be linked to an inducible pathway for PG synthesis. We examined the expression of the recently cloned inducible microsomal PGE synthase (mPGES) in synoviocytes from patients with rheumatoid arthritis, its modulation by cytokines and dexamethasone, and its linkage to the inducible cyclooxygenase-2. Northern blot analysis showed that IL-1β or TNF-α treatment induces mPGES mRNA from very low levels at baseline to maximum levels at 24 h. IL-1β-induced mPGES mRNA was inhibited by dexamethasone in a dose-dependent fashion. Western blot analysis demonstrated that mPGES protein was induced by IL-1β, and maximum expression was sustained for up to 72 h. There was a coordinated up-regulation of cyclooxygenase-2 protein, although peak expression was earlier. Differential Western blot analysis of the microsomal and the cytosolic fractions revealed that the induced expression of mPGES protein was limited to the microsomal fraction. The detected mPGES protein was catalytically functional as indicated by a 3-fold increase of PGES activity in synoviocytes following treatment with IL-1β; this increased synthase activity was limited to the microsomal fraction. In summary, these data demonstrate an induction of mPGES in rheumatoid synoviocytes by proinflammatory cytokines. This novel pathway may be a target for therapeutic intervention for patients with arthritis.